United Therapeutics reported a positive Phase 3 trial for ralinepag in pulmonary arterial hypertension, tying the drug to a 55% reduction in risk of clinical worsening. The company plans to file for U.S. approval this year and posited a 2027 launch if regulators accept the data. The Phase 3 result positions United Therapeutics to challenge an established class incumbent and could reshape competitive dynamics in PAH. Management linked the outcome to a planned regulatory submission and commercialization strategy. Investors view the success as a key value inflection for United Therapeutics, with the company poised to translate the Phase 3 win into near‑term filings and long‑term market opportunity in a specialty cardiopulmonary indication.